Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
50.49
USD
+2.25%
-0.79%
+41.91%
Presentation Operator MessageOperator (Operator)Good afternoon, ladies and gentlemen, and welc...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing
11/05
MT
Crinetics Pharmaceuticals Q1 Net Loss Widens
10/05
MT
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
10/05
CI
Transcript : Crinetics Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
10/05
Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating
07/05
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
18/04
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing
27/03
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing
23/03
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing
23/03
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing
21/03
MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating
20/03
MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating
20/03
MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating
20/03
MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating
20/03
MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
19/03
MT
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
19/03
MT
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
19/03
MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call
19/03
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
19/03
RE
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly
19/03
CI
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating
13/03
MT
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate
13/03
MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call
13/03
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
13/03
CI
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating
08/03
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
More about the company
Last Close Price
50.49
USD
Average target price
61.64
USD
Spread / Average Target
+22.09%
Consensus
1st Jan change
Capi.
+41.91% 3.98B +29.77% 49.46B +1.00% 42.58B +50.35% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B -1.62% 11.98B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**